Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.
Eli Lilly and Company has agreed to acquire privately-held biotechnology company Disarm Therapeutics for an upfront payment of $135m.
HitGen announces it has entered into a definitive agreement with Ligand Pharmaceuticals to acquire Vernalis (R&D) Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research.
Molecular engineering company Scribe Therapeutics has entered into a research collaboration with Biogen for the development of CRISPR-based genetic medicines for neurological diseases.
Bristol Myers Squibb (BMS) has signed an agreement to acquire clinical-stage biopharmaceutical company MyoKardia for $13.1bn.
Covis Group has agreed to acquire US-based commercial-stage biopharmaceutical company AMAG Pharmaceuticals for about $498m on a fully diluted basis.
Pfizer has announced an equity investment of $200m to purchase a 9.90% stake in biopharmaceutical company CStone Pharmaceuticals.
Biotechnology company Orgenesis has signed an agreement to acquire US-based regenerative medicine company Koligo Therapeutics.
Permira, the global private equity firm, today announced that a company backed by the Permira funds has agreed to acquire Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS) from funds advised by Apax Partners.
OnKure, a leader in discovery and development of next generation histone deacetylase (HDAC) inhibitors, entered into a clinical trial collaboration and supply agreement with Pfizer to support the clinical proof of concept study for MEKTOVI (binimetinib) in combination with OKI-179, a highly potent and tolerable Class I HDAC inhibitor currently in Phase I for the treatment of NRAS melanoma.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.